



Syncom Formulations (India) Limited

A WHO-GMP & ISO 9001-2000 Certified Company

CIN No.: L24239MH1988PLC047759

SYNCOM/SE/2024-25

12th August, 2024

Online filing at: www.listing.bseindia.com and
<https://neaps.nseindia.com/NEWLISTINGCORP/login.jsp>

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai (M.H.) 400 001
BSE CODE:524470

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400051
NSE SYMBOL: SYNCOMF

Subject: Regulation 33(3) of SEBI (LODR) Regulations, 2015- Submission of the Un-Audited Standalone and Consolidated Financial Results along with Limited Review Report thereon for the Quarter ended 30th June, 2024.

Dear Sir/Ma'am,

This is in continuation of our letter no. **SYNCOM/SE/2024-25** dated 2nd August 2024 regarding intimation of Board meeting for consideration and approval of Quarterly Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2024.

Pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015, we are pleased to submit the Un-Audited Standalone and Consolidated Financial Results along with Limited Review Report thereon for the Quarter ended 30th June, 2024, in PDF Format, which were also approved and recommended by the Audit Committee and further approved by the Board of Directors at their meeting held on Monday, 12th August, 2024.

The Board Meeting was commenced at 4:00 P.M. and concluded at 4:30 P.M.

The Financial Results will also be published in widely circulated English & Marathi (Vernacular) newspaper in the prescribed format within the stipulated time period.

We are also in process to file the aforesaid financial results in XBRL format within the stipulated time and same shall also be hosted at the website of the company.

You are requested to take on record the above said Un-Audited Standalone and Consolidated Financial Results along with Limited Review Report for your reference and record.

Thanking You
Yours Faithfully
For, **SYNCOM FORMULATIONS (INDIA) LIMITED**

**CS VAISHALI AGRAWAL
COMPANY SECRETARY &
COMPLIANCE OFFICER**

Encl: *Unaudited Standalone and Consolidated Financial Results and Limited Review Report.*

Bringing a smile on every face...

Regd. Off. : 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (East), MUMBAI-400 093, INDIA, Tel.: 91-022-30887744-54, Fax: 91-022-30887755, Email: sfil87@syncomformulations.com

Works : 256-257, Sector-I, PITHAMPUR, Dist.-Dhar, M.P. - 454 775, INDIA, Tel.: 91-07292-403122, 407039, Fax: 91-07292-253404, Email: assistant2@sfil.in

Corp. Off. : 207, Saket Nagar, Near Saket Club, INDORE - 452 018, INDIA. Tel. : 91-0731-2700458, Email : finance@sfil.in

Website : <http://www.sfil.in>



SYNCOM FORMULATIONS (INDIA) LIMITED

Regd. Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works - 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2024

(Rs. In Lakhs) (Except EPS)

S. No.	Particulars	Quarter Ended			Year Ended
		30-06-2024	31-03-2024	30-06-2023	31-03-2024
		Unaudited	Audited*	Unaudited	Audited
1	Revenue from Operations	8683.09	7326.63	5936.43	25835.96
2	Other Income	131.31	287.08	187.74	1310.06
3	Total Income (1 + 2)	8814.40	7613.71	6124.17	27146.02
4	EXPENSES				
	(a) Cost of materials consumed	5303.13	3787.87	2265.31	13152.91
	(b) Purchases of Stock-in-Trade	406.08	488.61	914.08	2620.83
	(c) Changes in inventories of finished goods, Stock-in- Trade and work-in-progress	(263.29)	(20.04)	390.53	(218.10)
	(d) Employee benefits expense	964.92	869.23	762.81	3505.77
	(e) Finance costs	38.65	116.97	112.17	444.87
	(f) Depreciation and amortization expense	130.00	129.77	110.00	472.23
	(g) Other expenses	1225.22	1320.45	987.93	3989.12
	Total expenses (4)	7804.71	6692.86	5542.83	23967.63
5	Profit/(loss) before exceptional items and tax (3- 4)	1009.69	920.85	581.34	3178.39
6	Exceptional Items	0.00	0.00	0.00	(2.39)
7	Profit/(loss) before tax (5 - 6)	1009.69	920.85	581.34	3176.00
8	Tax expense:				
	(1) Current tax	243.77	241.73	160.30	758.25
	(2) Deferred tax	3.06	4.27	(3.81)	55.43
9	Profit (Loss) for the period from continuing operations (7-8)	762.86	674.85	424.85	2362.32
10	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00
11	Tax expense of discontinued operations	0.00	0.00	0.00	0.00
12	Profit/(loss) from Discontinued operations (after tax) (10-11)	0.00	0.00	0.00	0.00
13	Profit/(loss) for the period (9 + 12)	762.86	674.85	424.85	2362.32
14	Other Comprehensive Income				
	A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	B (i) Items that will be reclassified to profit or loss	275.93	164.57	206.77	681.39
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
15	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	1038.79	839.42	631.62	3043.71
16	Paid up Share Capital of the Company (Face Value 1/-)	9400.00	9400.00	9400.00	9400.00
17	Reserves excluding revaluation reserves				19245.18
18	Earnings per equity share (for continuing operation):				
	(1) Basic	0.11	0.09	0.07	0.32
	(2) Diluted	0.11	0.09	0.07	0.32
19	Earnings per equity share (for discontinued operation):				
	(1) Basic	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00
20	Earnings per equity share (for discontinued & continuing operations)				
	(1) Basic	0.11	0.09	0.07	0.32
	(2) Diluted	0.11	0.09	0.07	0.32

Place: Indore

Date: 12/08/2024

For, Syncom Formulations (India) Limited

Kedarmal Shankarlal Bankda
Chairman & Wholetime Director

DIN: 00023050





SYNCOM FORMULATIONS (INDIA) LIMITED

Regd Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works :- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

STANDALONE STATEMENT OF SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY RESULTS FOR THE QUARTER ENDED 30TH JUNE 24

S. No.	Particulars	Quarter Ended			Year Ended
		30-06-2024	31-03-2024	30-06-2023	31-03-2024
		Unaudited	Audited*	Unaudited	Audited
1	Segment Revenue				
	a) Pharmaceuticals Drugs & Formulations	8585.33	7302.70	5559.41	25,672.79
	b) Trading of Commodities	132.41	213.93	456.98	1,071.34
	c) Renting of Property	96.66	97.08	107.78	401.89
	Total Segment Revenue	8814.40	7613.71	6124.17	27,146.02
	Less: Inter Segment Revenue	0.00	0.00	0.00	-
	Revenue from Operations	8814.40	7613.71	6124.17	27,146.02
2	Segment Results Profit(+)/Loss(-) before tax and interest from each segment				
	a) Pharmaceuticals Drugs & Formulations	955.36	939.46	595.98	3,232.76
	b) Trading of Commodities	4.39	19.92	-5.70	18.49
	c) Renting of Property	88.59	78.44	103.23	369.62
	Total Profit before tax	1048.34	1037.82	693.51	3,620.87
	Less: i) Interest	38.65	116.97	112.17	444.87
	ii) Other Un-allocable Expenditure	0.00	0.00	0.00	-
	Profit before tax	1009.69	920.85	581.34	3,176.00
3	(Segment Asset-Segment Liabilities)				
	Segment Asset				
	a) Pharmaceuticals Drugs & Formulations	29437.25	33390.18	32038.86	33,390.18
	b) Trading of Commodities	964.42	1026.45	980.14	1,026.45
	c) Renting of Property	4733.45	4733.45	4733.45	4,733.45
	Total Segment Asset	35135.12	39150.08	37752.45	39,150.08
	Un-allocable Assets	0.00	0.00	0.00	-
	Net Segment Asset	35135.12	39150.08	37752.45	39,150.08
	Segment Liabilities				
	a) Pharmaceuticals Drugs & Formulations	5050.13	10181.37	11095.28	10,181.37
	b) Trading of Commodities	167.45	151.93	260.49	151.93
	c) Renting of Property	181.32	171.60	163.56	171.60
	Total Segment Liabilities	5398.90	10504.90	11519.33	10,504.90
	Un-allocable Liabilities	0.00	0.00	0.00	-
	Net Segment Liabilities	5398.90	10504.90	11519.33	10,504.90

Notes:-

- The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 12/08/2024.
- These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.
- The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required.
- As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been conducted for the quarter ended on 30th June, 2024. The report does not have any impact on the above results and notes which needs explanation.
- Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.

Place: Indore

Date: 12/08/2024

For, Syncom Formulations (India) Limited



Kedarmal Shankarlal Bankda
Chairman & Wholetime Director

DIN: 00023050

Limited Review Report on Un-audited Standalone Financial Results for the Quarter & Third Month ended 30th June, 2024 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015

To,
The Board of Directors
SYNCOM FORMULATIONS (INDIA) LIMITED
Indore (M.P.)

We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **SYNCOM FORMULATIONS (INDIA) LIMITED ("the Company")**, for the period ended June, 30, 2024 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended including relevant circular issued by the SEBI from time to time.

This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting ("IND AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other Accounting principles generally accepted in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended, including relevant circulars issued by the SEBI from time to time. Our responsibility is to issue a report on these Financial Statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "*Review of Interim Financial Information performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Indore
Date: 12th August, 2024

For, Sanjay Mehta & Associates
Chartered Accountants
FRN: 011524C


CA Manish Mittal
(Partner)
M. No. 079452
UDIN: 24079452BJZYB4004





SYNCOM FORMULATIONS (INDIA) LIMITED

Regd Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works :- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2024

(Rs. In Lakhs) (Except EPS)

S. No.	Particulars	Quarter Ended			Year Ended
		30-06-2024	31-03-2024	30-06-2023	31-03-2024
		Unaudited	Audited*	Unaudited	Audited
1	Revenue from Operations	8725.54	7457.29	5983.58	26338.71
2	Other Income	133.84	309.84	187.47	1352.59
3	Total Income (1 + 2)	8859.38	7767.13	6171.05	27691.30
4	EXPENSES		0.00		
	(a) Cost of materials consumed	5303.13	3787.87	2265.31	13152.91
	(b) Purchases of Stock-in-Trade	428.61	501.95	921.42	2710.59
	(c) Changes in inventories of finished goods, Stock-in- Trade and work-in-progress	(280.40)	(20.04)	368.22	(175.46)
	(d) Employee benefits expense	964.92	869.23	762.81	3505.77
	(e) Finance costs	39.03	119.51	112.17	447.41
	(f) Depreciation and amortization expense	130.00	129.77	110.00	472.23
	(g) Other expenses	1263.88	1375.84	1019.85	4180.16
	Total expenses (4)	7849.17	6764.13	5559.78	24293.61
5	Profit/(loss) before exceptional items and tax (3- 4)	1010.21	1003.00	611.27	3397.69
6	Exceptional Items	0.00	0.00	0.00	(2.39)
7	Profit/(loss) before tax (5 - 6)	1010.21	1003.00	611.27	3395.30
8	Tax expense:		0.00		
	(1) Current tax	243.90	258.28	175.45	808.45
	(2) Deferred tax	3.06	4.27	(3.81)	55.43
9	Profit (Loss) for the period from continuing operations (7-8)	763.25	740.45	439.63	2531.42
10	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00
11	Tax expense of discontinued operations	0.00	0.00	0.00	0.00
12	Profit/(loss) from Discontinued operations (after tax) (10-11)	0.00	0.00	0.00	0.00
13	Profit/(loss) for the period (9 + 12)	763.25	740.45	439.63	2531.42
14	Other Comprehensive Income				
	A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	B (i) Items that will be reclassified to profit or loss	275.93	164.57	206.77	681.39
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
15	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	1039.18	905.02	646.40	3212.81
16	Paid up Share Capital of the Company (Face Value 1/-)	9400.00	9400.00	9400.00	9400.00
17	Reserves excluding revaluation reserves				19414.28
18	Earnings per equity share (for continuing operation):				
	(1) Basic	0.11	0.10	0.07	0.34
	(2) Diluted	0.11	0.10	0.07	0.34
19	Earnings per equity share (for discontinued operation):				
	(1) Basic	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00
20	Earnings per equity share (for discontinued & continuing operations)				
	(1) Basic	0.11	0.10	0.07	0.34
	(2) Diluted	0.11	0.10	0.07	0.34

Place: Indore

Date: 12/08/2024

For, Syncom Formulations (India) Limited

Kedarmal Shankarlal Bankda
Chairman & Wholetime Director

DIN: 00023050



SYNCOM FORMULATIONS (INDIA) LIMITED

Regd. Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

CONSOLIDATED STATEMENT OF SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY RESULTS FOR THE QUARTER ENDED 30TH JUNE 24

S. No.	Particulars	Quarter Ended			Year Ended
		30-06-2024	31-03-2024	30-06-2023	31-03-2024
		Unaudited	Audited*	Unaudited	Audited
1	Segment Revenue				
	a) Pharmaceuticals Drugs & Formulations	8630.31	7454.52	5606.59	26,218.06
	b) Trading of Commodities	132.41	213.93	456.98	1,071.34
	c) Renting of Property	96.66	98.67	107.48	401.89
	Total Segment Revenue	8859.38	7767.12	6171.05	27,691.29
	Less: Inter Segment Revenue	0.00	0.00	0.00	-
	Revenue from Operations	8859.38	7767.12	6171.05	27,691.29
2	Segment Results Profit(+)/Loss(-) before tax and interest from each segment				
	a) Pharmaceuticals Drugs & Formulations	956.25	1022.55	626.21	3,454.60
	b) Trading of Commodities	4.39	19.92	-5.70	18.49
	c) Renting of Property	88.59	80.03	102.93	369.62
	Total Profit before tax	1049.23	1122.50	723.44	3,842.71
	Less: i) Interest	39.03	119.51	112.17	447.41
	ii) Other Un-allocable Expenditure	0.00		0.00	-
	Profit before tax	1010.20	1002.99	611.27	3,395.30
3	(Segment Asset-Segment Liabilities)				
	Segment Asset				
	a) Pharmaceuticals Drugs & Formulations	29849.25	34706.49	32085.85	34,706.49
	b) Trading of Commodities	964.42	1026.45	980.14	1,026.45
	c) Renting of Property	4733.45	4733.45	4733.45	4,733.45
	Total Segment Asset	35547.12	40466.39	37799.44	40,466.39
	Un-allocable Assets	0.00	0.00	0.00	-
	Net Segment Asset	35547.12	40466.39	37799.44	40,466.39
	Segment Liabilities				
	a) Pharmaceuticals Drugs & Formulations	5241.86	11328.58	11127.46	11,328.58
	b) Trading of Commodities	167.45	151.93	260.49	151.93
	c) Renting of Property	181.32	171.60	163.56	171.60
	Total Segment Liabilities	5590.63	11652.11	11551.51	11,652.11
	Un-allocable Liabilities	0.00	0.00	0.00	-
	Net Segment Liabilities	5590.63	11652.11	11551.51	11,652.11


Notes:-

- The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 12/08/2024.
- These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.
- The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required.
- As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been conducted for the quarter ended on 30th June, 2024. The report does not have any impact on the above results and notes which needs explanation.
- Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.

Place: Indore

Date: 12/08/2024

For, Syncom Formulations (India) Limited


Kedarmal Shankarlal Bankdar
 Chairman & Wholetime Director
 DIN: 00023060

**Limited Review Report on Un-audited Consolidated Financial Results for the Quarter and
Three Months ended 30th June, 2024 pursuant to Regulation 33 of the SEBI (LODR)
Regulations, 2015**

To,
The Board of Directors
SYNCOM FORMULATIONS (INDIA) LIMITED
Indore (M.P.)

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of **SYNCOM FORMULATIONS (INDIA) LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the period ended June 30, 2024 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended including relevant circular issued by the SEBI from time to time.
2. This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting ("IND AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other Accounting principles generally accepted in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended, including relevant circulars issued by the SEBI from time to time. Our responsibility is to issue a report on these Financial Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. The Statement includes the results of the following entity:


S. No.	Name of the Company	Relationship with the Holding Company
1.	Santa Biotech Pvt. Ltd.	Wholly Owned Subsidiary
2.	Synmex Pharma Pvt. Ltd.	Wholly Owned Subsidiary
3.	Vincit Biotech International Pvt. Ltd.	Wholly Owned Subsidiary




5. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Sanjay Mehta & Associates
Chartered Accountants
FRN: 011524C

Place: Indore
Date: 12th August 2024


CA Manish Mittal
(Partner)
M. No. 079452
UDIN: 24079452BJZYIC1987



No.	Name of the Company	Relationship with the Reporting Company
1	Sanki through Pvt. Ltd.	Wholly owned subsidiary
2	Sanki Pvt. Ltd.	Wholly owned subsidiary
3	Vinay Electrical Pvt. Ltd.	Wholly owned subsidiary

